Clinical Trial Update: Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma [Phase 2]

View source ↗

Summary

Phase 2 trial of linsitinib in relapsed or refractory Ewing sarcoma has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Drugs mentioned

• Linsitinib (linsitinib)

Snippet

Sponsor: University of Oxford | Conditions: Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-03